BACKGROUND: Fibrosis progression is the common consequence of most chronic liver diseases. AIMS: To evaluate the performance of Collagen Proportionate Area (CPA) and ELF using Ishak's score in patients with chronic liver diseases. METHODS: Retrospective analysis of medical data from patients on whom a liver biopsy was performed as part of the diagnostic assessment. CPA was calculated by using digital image analysis and then compared with Ishak and ELF scores. RESULTS: 143 patients (84 men (59%); mean age 48.8 ± 12.8 years) were evaluated. Patients were mainly affected by viral hepatitis (92 HCV and 8 HBV). CPA and ELF values increased with worsening Ishak stage (P < 0.001) and their median values were significantly different among Ishak sta...
Background and Aims:\u2002 Current histological scoring systems do not subclassify cirrhosis. Comput...
Objectives: The aim of the study was to investigate the interobserver agreement for categorical and ...
Background & AimsOne-year survival in cirrhosis ranges from 1 to 57% depending on the clinical stage...
Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease in ne...
BACKGROUND: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tis...
Background: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tis...
Background & Aims Histopathological scoring of liver fibrosis mainly measures architectural abnormal...
Background: No prognostic tools are established for alcohol-related liver disease (ALD). Collagen pr...
Liver disease has been targeted as the fifth most common cause of death worldwide and tends to stead...
Histopathological scoring of disease stage uses descriptive categories without measuring the amount ...
Introduction/aims: Liver fibrosis assessment is a key issue in the evaluation of nonalcoholic fatty ...
Histopathological scoring of disease stage uses descriptive categories without measuring the amount ...
Introduction and objectives: A crucial issue when appraising the performance of non-invasive markers...
Background: Collagen proportional area (CPA) determined by quantitative digital image analysis bette...
Background: Evaluation of fibrosis is crucial in the assessment of chronic hepatitis C (CHC). The en...
Background and Aims:\u2002 Current histological scoring systems do not subclassify cirrhosis. Comput...
Objectives: The aim of the study was to investigate the interobserver agreement for categorical and ...
Background & AimsOne-year survival in cirrhosis ranges from 1 to 57% depending on the clinical stage...
Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease in ne...
BACKGROUND: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tis...
Background: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tis...
Background & Aims Histopathological scoring of liver fibrosis mainly measures architectural abnormal...
Background: No prognostic tools are established for alcohol-related liver disease (ALD). Collagen pr...
Liver disease has been targeted as the fifth most common cause of death worldwide and tends to stead...
Histopathological scoring of disease stage uses descriptive categories without measuring the amount ...
Introduction/aims: Liver fibrosis assessment is a key issue in the evaluation of nonalcoholic fatty ...
Histopathological scoring of disease stage uses descriptive categories without measuring the amount ...
Introduction and objectives: A crucial issue when appraising the performance of non-invasive markers...
Background: Collagen proportional area (CPA) determined by quantitative digital image analysis bette...
Background: Evaluation of fibrosis is crucial in the assessment of chronic hepatitis C (CHC). The en...
Background and Aims:\u2002 Current histological scoring systems do not subclassify cirrhosis. Comput...
Objectives: The aim of the study was to investigate the interobserver agreement for categorical and ...
Background & AimsOne-year survival in cirrhosis ranges from 1 to 57% depending on the clinical stage...